drugset
drugset / Trial / NCT06794008

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

NCT06794008 ↗

Phase 2 Recruiting 50 enrolled Peking University People's Hospital
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate the efficacy and safety of BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells in the treatment of autoimmune diseases.

Timeline

Start
2024-12-26
Primary completion
2027-12-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BCMA-CD19 CAR-T therapy Cell therapy 3e+06 cells/kg Intravenous

Indications

Behcet disease Sjogren syndrome acquired thrombotic thrombocytopenic purpura anti-neutrophil cytoplasmic antibody-associated vasculitis antiphospholipid syndrome immunoglobulin G4-related sclerosing disease myositis disease systemic lupus erythematosus systemic sclerosis